United States: GRAS since 2012
In the US, allulose is used under the "generally recognized as safe" (GRAS) pathway. The FDA's GRAS notice inventory lists 11 D-psicose notices closed with an "FDA has no questions" letter, starting with GRN 400 in June 2012 and most recently GRN 1309 in July 2026, with another notice pending.
GRAS is not a formal food additive approval: companies assess safety themselves and notify the FDA, a pathway the Center for Science in the Public Interest (CSPI) criticizes. CSPI rates allulose "cut back" and, in 2019, asked the FDA to consider a label warning that excess consumption may cause diarrhea or other digestive effects.
Australia and New Zealand: approved in 2024
Food Standards Australia New Zealand approved D-allulose as a novel food in August 2024 after a full risk assessment and concluded it "would pose no public health and safety concerns" as proposed. The approval came with conditions: an energy factor of 2 kJ/g for labels, exclusion from the sugars line, maximum use levels by food category, and a mandatory advisory statement that excess consumption may have a laxative effect for certain foods.
FSANZ also flagged a gap worth knowing about. The human studies it reviewed excluded people with diabetes, liver or kidney disorders, and pregnant or breastfeeding women, so there is little direct safety data for those groups.
Japan, South Korea, Mexico and others
Per the FSANZ report, allulose is sold in Japan without specific approval and permitted in South Korea, both treating it as zero calories, and Mexico approved it as a non-caloric sweetener in 2017. FoodNavigator adds China and Singapore.
European Union and UK: not authorized
In the EU, allulose is a novel food (not eaten to a significant degree before May 1997), so it needs authorization before sale. The European Commission's application register lists allulose applications from CJ-Tereos, Petiva and Samyang in 2018 and Savanna Ingredients in 2020. A review that checked the Union list on August 10, 2026 found no authorization.
The only finished EFSA opinion so far, published in June 2025, concerned Petiva's application. EFSA concluded that safety "cannot be established" because the applicant never answered requests for more data on identity, production, use levels, genotoxicity and longer-term human studies. That is an incomplete dossier, not evidence of harm, but allulose still cannot legally be sold as food in the EU.
The UK runs its own process after Brexit. The Food Standards Agency register shows an allulose application from Savanna Ingredients still at the risk assessment stage.
Canada
Allulose is not on Health Canada's List of Permitted Sweeteners for ordinary foods, and industry regulatory reviews report no completed novel food assessment for it. It does show up as a non-medicinal ingredient in some licensed natural health products, which is a separate regulatory category.